Clinical Trials in Ophthalmology - Study Results

Clinical Study to Evaluate the Effectiveness and Safety of Oral Memantine in Daily Doses of 20mg and 10mg in Patients with Open Angle Glaucoma at Risk for Glaucomatous Progression.

Paul A. Sidoti, MD

Corneal Endothelial Cell Counts Following Baerveldt Glaucoma Implant Surgery

Paul A. Sidoti, MD

Tube Versus Trabeculectomy (TVT)

Paul A. Sidoti, MD

Central Retinal Vein Occlusion (CRVO)

The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study

Richard Rosen, MD and Belinda Shirkey, MD

Diabetic Macular Edema

Protein Kinase C β Inhibitor - Diabetic Retinopathy Study 2 (PKC-DRS2)

Ronald Gentile, MD

A Controlled Study to Evaluate Retisert™, an Intravitreal Fluocinolone Acetonide Implant, in the Treatment of Patients with Diabetic Macular Edema

Ronald Gentile, MD

A Comparative Trial to Establish the Safety and Preliminary Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer), Given Every 6 Weeks for 12 to 30 Weeks to Patients with Clinically Significant Diabetic Macular Edema (CSME) Involving the Center of the Macula

Ronald Gentile, MD

Age Related Macular Degeneration

Transpupillary Thermotherapy (TTT) of Occult Subfoveal Neovascular Membranes in Patients with AMD

Richard B. Rosen, MD

A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Safety and Efficacy of rhuFab in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration

Ronald Gentile, MD

A Phase I/II, Single-Masked Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Dose Intravitreal Injections of rhuFabV2 in Combination With Verteporfin Photodynamic Therapy (Visudyne) in Subjects with Neovascular Age-Related Macular Degeneration

Ronald Gentile, MD

An Evaluation of Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15mg (0.5mL of 30mg/mL Anecortave Acetate Sterile Suspension) Versus Visudyne in Patient with Subfoveal Exudative Age-Related Macular Degeneration (AMD) Eligible for Initial Treatment with Photodynamic Therapy (PDT) Using Visudyne®

Richard B. Rosen, MD

Evaluation of the Preferential Hyperacuity Perimeter (PHP) Device, for Testing Intermediate AMD Patients, During Routine Eye Clinic Operation

Richard B. Rosen, MD

Microcurrent stimulation for the improvement of visual acuity in subjects with non-exudative age related macular degeneration (AMD) 

Richard B. Rosen, MD

An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects with Neovascular Age-Related Macular Degeneration who Have Completed the Treatment Phase of A Genentech-Sponsored Phase I or Phase II/III rhuFab V2 Study

Ronald Gentile, MD

Trial of the Safety, Tolerability and Pharmacokinetics of 3 mg/eye Intravitreal Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients with Exudative Age-Related Macular Degeneration

Richard B. Rosen, MD

A Phase IV, Open Label, Multi-Center, Trial of Maintenance Intravitreous Injections of Macugen® (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated with a Modality Resulting in Maculopathy Improvement, EOP 1023

Richard B. Rosen, MD

A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration

Richard B. Rosen, MD

Prophylactic Diode Laser Photocoagulation for the Prevention of Choroidal Neovascularization in Age-Related Macular Degeneration (AMD)

Ronald Gentile, MD

Safety and Efficacy of Intravitreal Injections of Eye001 (Anti-VEGF Pegylated Aptamer) in Patients with Age-Related Macular Degeneration (AMD)

Richard B. Rosen, MD

Safety, Tolerability, Pharmacokinetics, and Activity of rhuFab V2 in Subjects with Neovascular Age-Related Macular Degeneration

Ronald Gentile, MD

The Age-Related Eye Disease Study II (AREDS II): A Multi-center, Randomized Trial of Lutein, Zeaxanthin, and Long-Chain Omega-3 Fatty Acids (Docosahexaenoic acid [DHA] and Eicosapentaenoic acid [EPA]) in Age-Related Macular Degeneration

Richard B. Rosen, MD

Ophthalmologic Safety

A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients

Alessandra Bertolucci, MD

Retinal Detachment

A Safety and Efficacy Assessment of Chimeric Ribozyme to PCNA to Prevent Recurrence of Proliferative Vitreoretinopathy

Ronald Gentile, MD

A Randomized, Double-Masked, Placebo Controlled, Parallel Group, Multi-Center, Dose-Ranging Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects with Rhegmatogenous Retinal Detachment

Richard B. Rosen, MD

Safety, Pharmacokinetics, Immunogenicity, and Clinical Response to Multiple Subcutaneous Administrations of the Human Monoclonal Antibody to Human TNF-alpha (CNTO 148) in Patients With Intermediate Uveitis, Posterior Uveitis, or Panuveitis.

C. Michael Samson, MD

A 6-Week, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Anterior Segment in Patients with Anterior Uveitis

C. Michael Samson, MD

An 8-Week, Multicenter, Masked, Randomized Trial (with an 18-Week Masked Extension) to Assess the Safety and Efficacy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System Compared with Sham DEX PS DDS Applicator System in the Treatment of Non-Infectious Ocular Inflammation of the Posterior Segment in Patients with Intermediate Uveitis

C. Michael Samson, MD

Mycophenolate Mofetil in the Treatment of Chronic Non-Infectious Uveitis

C. Michael Samson, MD